PMID- 36142247
OWN - NLM
STAT- MEDLINE
DCOM- 20220926
LR  - 20220928
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 23
IP  - 18
DP  - 2022 Sep 7
TI  - Targeting NMDA Receptors at the Neurovascular Unit: Past and Future Treatments 
      for Central Nervous System Diseases.
LID - 10.3390/ijms231810336 [doi]
LID - 10336
AB  - The excitatory neurotransmission of the central nervous system (CNS) mainly 
      involves glutamate and its receptors, especially N-methyl-D-Aspartate receptors 
      (NMDARs). These receptors have been extensively described on neurons and, more 
      recently, also on other cell types. Nowadays, the study of their differential 
      expression and function is taking a growing place in preclinical and clinical 
      research. The diversity of NMDAR subtypes and their signaling pathways give rise 
      to pleiotropic functions such as brain development, neuronal plasticity, 
      maturation along with excitotoxicity, blood-brain barrier integrity, and 
      inflammation. NMDARs have thus emerged as key targets for the treatment of 
      neurological disorders. By their large extracellular regions and complex 
      intracellular structures, NMDARs are modulated by a variety of endogenous and 
      pharmacological compounds. Here, we will present an overview of NMDAR functions 
      on neurons and other important cell types involved in the pathophysiology of 
      neurodegenerative, neurovascular, mental, autoimmune, and neurodevelopmental 
      diseases. We will then discuss past and future development of NMDAR targeting 
      drugs, including innovative and promising new approaches.
FAU - Seillier, Celia
AU  - Seillier C
AUID- ORCID: 0000-0002-5965-3626
AD  - Normandie University, UNICAEN, INSERM, GIP Cyceron, Institute Blood and Brain 
      @Caen-Normandie (BB@C), UMR-S U1237, Physiopathology and Imaging of Neurological 
      Disorders (PhIND), 14000 Caen, France.
FAU - Lesept, Flavie
AU  - Lesept F
AD  - Lys Therapeutics, Cyceron, Boulevard Henri Becquerel, 14000 Caen, France.
FAU - Toutirais, Olivier
AU  - Toutirais O
AD  - Normandie University, UNICAEN, INSERM, GIP Cyceron, Institute Blood and Brain 
      @Caen-Normandie (BB@C), UMR-S U1237, Physiopathology and Imaging of Neurological 
      Disorders (PhIND), 14000 Caen, France.
AD  - Department of Immunology and Histocompatibility (HLA), Caen University Hospital, 
      CHU, 14000 Caen, France.
FAU - Potzeha, Fanny
AU  - Potzeha F
AD  - Lys Therapeutics, Cyceron, Boulevard Henri Becquerel, 14000 Caen, France.
FAU - Blanc, Manuel
AU  - Blanc M
AD  - Lys Therapeutics, Cyceron, Boulevard Henri Becquerel, 14000 Caen, France.
FAU - Vivien, Denis
AU  - Vivien D
AD  - Normandie University, UNICAEN, INSERM, GIP Cyceron, Institute Blood and Brain 
      @Caen-Normandie (BB@C), UMR-S U1237, Physiopathology and Imaging of Neurological 
      Disorders (PhIND), 14000 Caen, France.
AD  - Department of Clinical Research, Caen University Hospital, CHU, 14000 Caen, 
      France.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220907
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - 0 (Receptors, N-Methyl-D-Aspartate)
RN  - 3KX376GY7L (Glutamic Acid)
SB  - IM
MH  - *Central Nervous System Diseases/drug therapy
MH  - Glutamic Acid/metabolism
MH  - Humans
MH  - Neurons/metabolism
MH  - *Receptors, N-Methyl-D-Aspartate/metabolism
MH  - Synaptic Transmission
PMC - PMC9499580
OTO - NOTNLM
OT  - NMDA receptors
OT  - blood-brain barrier
OT  - central nervous system
OT  - excitotoxicity
OT  - inflammation
OT  - neurological diseases
OT  - therapeutic strategies
COIS- D.V. is the President of the Scientific Advisory Board of Lys Therapeutics and 
      co-inventor of the patent number PCT#WO2014187879; M.B. is the Chief Executive 
      Officer and co-founder of Lys Therapeutics; F.L. and F.P are employees in Lys 
      Therapeutics.
EDAT- 2022/09/24 06:00
MHDA- 2022/09/28 06:00
PMCR- 2022/09/07
CRDT- 2022/09/23 01:22
PHST- 2022/08/05 00:00 [received]
PHST- 2022/08/30 00:00 [revised]
PHST- 2022/09/02 00:00 [accepted]
PHST- 2022/09/23 01:22 [entrez]
PHST- 2022/09/24 06:00 [pubmed]
PHST- 2022/09/28 06:00 [medline]
PHST- 2022/09/07 00:00 [pmc-release]
AID - ijms231810336 [pii]
AID - ijms-23-10336 [pii]
AID - 10.3390/ijms231810336 [doi]
PST - epublish
SO  - Int J Mol Sci. 2022 Sep 7;23(18):10336. doi: 10.3390/ijms231810336.